Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions
Journal of Allergy and Clinical Immunology, Volume 116, No. 2, Year 2005
Notification
URL copied to clipboard!
Description
Background: Asthma is a chronic inflammatory disease with increasing incidence worldwide. Roflumilast is an oral, once-daily inhibitor of phosphodiesterase type 4 that prevents the breakdown of cyclic adenosine monophosphate levels, leading to inhibition of proinflammatory signaling. Objective: The objective of this study was to investigate the effects of repeated doses of 250 or 500 μg of roflumilast on asthmatic airway responses to allergen. Methods: Twenty-three patients with mild asthma with an FEV 1 of 70% of predicted value or greater were enrolled in a randomized, double-blind, placebo-controlled, 3-period crossover study. Patients participated in 3 treatment periods (7-10 days) separated by washout periods (2-5 weeks). Patients received 250 μg of oral roflumilast, 500 μg of roflumilast, or placebo once daily. Allergen challenge was performed at the end of each treatment period, followed by FEV1 measurements over the ensuing 24 hours. Results: Late asthmatic reactions (LARs) were reduced by 27% (P = .0110) and 43% (P = .0009) in patients treated with 250 and 500 μg of roflumilast, respectively, versus placebo. Roflumilast, 250 and 500 μg, also attenuated early asthmatic reactions by 25% (P = .0038) and 28% (P = .0046), although not to the same extent as LAR attenuation. Roflumilast was well tolerated. No serious adverse events or discontinuations caused by adverse events were reported. Conclusion: Once-daily oral roflumilast modestly attenuated early asthmatic reactions and, to a greater extent, LARs to allergen in patients with mild allergic asthma. Pronounced suppression of late responses in an allergen challenge model suggests that roflumilast might have anti-inflammatory activity, which could provide clinical efficacy in chronic inflammatory pulmonary diseases, such as asthma. © 2005 American Academy of Allergy, Asthma and Immunology.
Authors & Co-Authors
van Schalkwyk, Emmerentia M.
South Africa, Stellenbosch
Stellenbosch University
Strydom, K.
South Africa, Stellenbosch
Stellenbosch University
Williams, Zelda
Australia, Clayton
Faculty of Medicine, Nursing and Health Sciences
Venter, L.
South Africa, Johannesburg
Altana Madaus Pty Ltd.
Leichtl, S.
Norway
Nycomed
Schmid-Wirlitsch, C.
Norway
Nycomed
Bredenbröker, D.
Norway
Nycomed
Bardin, Philip G.
Australia, Clayton
Faculty of Medicine, Nursing and Health Sciences
Australia, Clayton
Monash Medical Centre
Statistics
Citations: 107
Authors: 8
Affiliations: 5
Identifiers
Doi:
10.1016/j.jaci.2005.04.023
ISSN:
00916749
Research Areas
Disability
Health System And Policy
Study Design
Cohort Study